Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
Following the sale, Lloyd retains direct ownership of 120,594 shares, which includes 30,624 restricted stock units (RSUs). The shares were sold to satisfy tax or other government withholding obligations related to the vesting of RSUs. The transaction occurs as CytomX maintains a strong financial position with more cash than debt on its balance sheet, and analysts have recently revised their earnings expectations upward. Discover more insights about CTMX and access comprehensive analysis of 1,400+ stocks with a InvestingPro subscription. The transaction occurs as CytomX maintains a strong financial position with more cash than debt on its balance sheet, and analysts have recently revised their earnings expectations upward. Discover more insights about CTMX and access comprehensive analysis of 1,400+ stocks with a InvestingPro subscription.
Following the sale, Lloyd retains direct ownership of 120,594 shares, which includes 30,624 restricted stock units (RSUs). The shares were sold to satisfy tax or other government withholding obligations related to the vesting of RSUs.
In other recent news, CytomX Therapeutics Inc (NASDAQ:CTMX). reported its fourth-quarter 2024 financial results, showcasing a remarkable revenue achievement. The company reported a total revenue of $138.1 million, significantly surpassing the forecast of $12.24 million. This impressive performance is primarily attributed to successful collaborations with major partners, including Bristol Myers (NYSE:BMY) Squibb, Moderna (NASDAQ:MRNA), Astellas, and Regeneron (NASDAQ:REGN). Additionally, CytomX has extended its cash runway to the second quarter of 2026, providing a solid financial foundation for future operations. However, the company has faced challenges, such as the discontinuation of the CX-9004 program with Amgen (NASDAQ:AMGN), which may impact future revenue streams. Despite these challenges, CytomX is optimistic about its ongoing clinical programs, notably CX-2051 and CX-8001, which are progressing well. The company plans to release initial Phase 1a data for CX-2051 in the first half of 2025 and initiate a combination study of CX-8001 with KEYTRUDA later that year. These developments reflect CytomX’s strategic focus on advancing its therapeutic pipeline and addressing unmet needs in oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.